Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

'Challenging Quarter' For Sanofi As Questions Hang Over Diabetes Franchise

Executive Summary

"A somewhat challenging quarter," was how Sanofi CEO Olivier Brandicourt described the second three months of 2016, but analysts say there were no surprises in the downward trajectory of Sanofi's fortunes. There was also little news on Sanofi's pursuit of Medivation.

Advertisement

Related Content

Sanofi’s Franchise Defense Sees Biosimilar Insulin Lispro Under EU Review
Shire Looks To Build Around Xiidra, Sanofi Faces Toujeo Challenge, Amgen Downplays Romosozumab Data
Sanofi Joins Google’s Verily In Diabetes Venture
Sanofi, Google’s Verily Enter Diabetes JV To Produce Joined Up Solutions
No Fanfare For US Approval Of Sanofi's GLP-1 Adlyxin
Amgen Plugs Away On Repatha, With Hope For New Monthly Product
Medivation Hopes Details On Talazoparib Will Inspire Heightened M&A Bidding
Medivation Rejects Sanofi's Latest Bid, But Enters Confidential Negotiations

Topics

Advertisement
UsernamePublicRestriction

Register

SC097024

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel